ATE478148T1 - Verwendung von il-10 rezeptor beta antagonistische antikörper zur hemmung einer il- tif/il-21 induktion von akutphasen-proteine - Google Patents

Verwendung von il-10 rezeptor beta antagonistische antikörper zur hemmung einer il- tif/il-21 induktion von akutphasen-proteine

Info

Publication number
ATE478148T1
ATE478148T1 AT07002409T AT07002409T ATE478148T1 AT E478148 T1 ATE478148 T1 AT E478148T1 AT 07002409 T AT07002409 T AT 07002409T AT 07002409 T AT07002409 T AT 07002409T AT E478148 T1 ATE478148 T1 AT E478148T1
Authority
AT
Austria
Prior art keywords
molecules
acute phase
tif
inhibit
induction
Prior art date
Application number
AT07002409T
Other languages
English (en)
Inventor
Laure Dumoutier
Jean-Christophe Renauld
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Application granted granted Critical
Publication of ATE478148T1 publication Critical patent/ATE478148T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
AT07002409T 2000-07-27 2001-06-27 Verwendung von il-10 rezeptor beta antagonistische antikörper zur hemmung einer il- tif/il-21 induktion von akutphasen-proteine ATE478148T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62661700A 2000-07-27 2000-07-27

Publications (1)

Publication Number Publication Date
ATE478148T1 true ATE478148T1 (de) 2010-09-15

Family

ID=24511131

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01952260T ATE365801T1 (de) 2000-07-27 2001-06-27 Modulierung durch il-tif/interleukin-21
AT07002409T ATE478148T1 (de) 2000-07-27 2001-06-27 Verwendung von il-10 rezeptor beta antagonistische antikörper zur hemmung einer il- tif/il-21 induktion von akutphasen-proteine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01952260T ATE365801T1 (de) 2000-07-27 2001-06-27 Modulierung durch il-tif/interleukin-21

Country Status (9)

Country Link
EP (2) EP1305419B1 (de)
JP (1) JP4113773B2 (de)
CN (3) CN100448994C (de)
AT (2) ATE365801T1 (de)
AU (1) AU7303301A (de)
CA (1) CA2416820A1 (de)
DE (2) DE60142861D1 (de)
ES (1) ES2349312T3 (de)
WO (1) WO2002010393A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US7307161B1 (en) 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
US20030023033A1 (en) * 2001-07-26 2003-01-30 Laure Dumoutier Novel class II cytokine receptors and uses thereof
US20030012788A1 (en) 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
EP1326974B1 (de) * 2000-10-13 2006-12-27 Eli Lilly And Company Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
US7638604B2 (en) 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
EP1546358A4 (de) 2002-03-22 2006-06-07 Zymogenetics Inc Anti-il-tif-antikörper und verfahren zur verwendung bei entzündung
WO2004003156A2 (en) 2002-07-01 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Il-21 as a regulator of immunoglobin production
WO2004024076A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
EP1731163A2 (de) * 2002-10-11 2006-12-13 Novo Nordisk A/S Behandlung von allergischen Zuständen durch Verwendung von IL-21
WO2004032953A1 (en) * 2002-10-11 2004-04-22 Novo Nordisk A/S Treatment of allergic conditions by use of il 21
KR20060022289A (ko) * 2003-06-23 2006-03-09 제네틱스 인스티튜트, 엘엘씨 인터류킨-22 에 대한 항체 및 그의 용도
JP2009518314A (ja) 2005-12-02 2009-05-07 ジェネンテック・インコーポレーテッド Ｉｌ−２２に結合する抗体およびｉｌ−２２ｒに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
IT1404858B1 (it) 2011-02-21 2013-12-09 Milano Politecnico Supporto anti-sismico.
KR20230061392A (ko) * 2020-08-05 2023-05-08 신테카인, 인크. 수용체 쌍형성과 관련된 조성물 및 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843697A (en) 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
DE19848683B4 (de) 1998-10-22 2004-05-06 Basf Ag Verbundschichtplatte
US6331613B1 (en) * 1998-10-26 2001-12-18 Ludwig Institue For Cancer Research Isolated nucleic acid molecules which encode T cell inducible factors (TIFS), the proteins encoded, and uses thereof
NZ515678A (en) * 1999-04-28 2004-01-30 Genetics Inst Human GIL-19/AE289 proteins and polynucleotides encoding same
AU5047600A (en) * 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
CA2393369A1 (en) * 1999-12-03 2001-06-07 Zymogenetics, Inc. Human cytokine receptor

Also Published As

Publication number Publication date
CN100497628C (zh) 2009-06-10
EP1806404B1 (de) 2010-08-18
CN100448994C (zh) 2009-01-07
CA2416820A1 (en) 2002-02-07
EP1305419B1 (de) 2007-06-27
WO2002010393A3 (en) 2003-01-30
CN1796558A (zh) 2006-07-05
ES2349312T3 (es) 2010-12-29
DE60129137D1 (de) 2007-08-09
JP4113773B2 (ja) 2008-07-09
EP1305419A2 (de) 2003-05-02
DE60142861D1 (de) 2010-09-30
CN1443241A (zh) 2003-09-17
AU7303301A (en) 2002-02-13
CN101423551A (zh) 2009-05-06
EP1806404A1 (de) 2007-07-11
WO2002010393A2 (en) 2002-02-07
JP2004504842A (ja) 2004-02-19
ATE365801T1 (de) 2007-07-15

Similar Documents

Publication Publication Date Title
DE60142861D1 (de) Verwendung von IL-10 Rezeptor beta antagonistische Antikörper zur Hemmung einer IL-TIF/IL-21 Induktion von Akutphasen-Proteine
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
CY1112101T1 (el) Νευροτροφικοι παραγοντες
CY1121580T1 (el) ΝΕΟΙ ΠΡΟΑΓΩΓΕΙΣ β-ΑΚΤΙΝΗΣ ΚΑΙ RPS21 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
CY1108175T1 (el) ΠΟΛΥΠΕΠΤΙΔΙΟ DcR3, ΟΜΟΛΟΓΟ TNFR
SV2008002972A (es) Composiciones, metodos y usos de anticuerpos humanos anti-il-23 ref. cen5117sv
ATE500323T1 (de) Subtilisin-variante
DK1257648T3 (da) Antagonistiske selektive bindingsmidler af osteoprotegerin-bindingsprotein
DE60334460D1 (de) Antikörper spezifisch für das tau-protein des zentralen nervensystems
ATE491722T1 (de) Herstellung und reinigung von il-29
ATE348633T1 (de) Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
ATE408624T1 (de) Verfahren zur reinigung von fsh
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
CY1111371T1 (el) Αντισωματα bag3 για χρηση σε ερευνα, διαγνωση και θεραπεια ασθενειων που σχετιζονται με κυτταρικο θανατο
ATE536369T1 (de) Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
GEAP202516650A (en) Stabilized pre-fusion hmpv fusion proteins
DE69912839D1 (de) Nrihydroxstilbene enthaltende produkte und deren derivate und verfahren zur deren herstellung und ihre verwendung
ATE191568T1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
TR200201119T2 (tr) İnsan alfa1G-C-türü kalsiyum kanalı kodlayan DNA.
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
AR022150A1 (es) Acidos nucleicos derivados de monocitos y composiciones y metodos relacionados
ATE350387T1 (de) Verfahren zur reinigung von molekülen unter verwendung von unverzweigten alkyldiolen mit einständigen hydroxylgruppen
DE602006009901D1 (de) Verfahren zur herstellung von 7-ethyl-10-hydroxycamptothecin
EP1358207A4 (de) Sol-fusin: verwendung von gp64-6his zur katalysierung der membranfusion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties